Last reviewed 2026-04-19 · How we verify

OT202 conc 0.1%

Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 2 active Small molecule

OT202 conc 0.1% is a Small molecule drug developed by Ocumension Therapeutics (Shanghai) Co., Ltd. It is currently in Phase 2 development. Also known as: Investigational product.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	OT202 conc 0.1%
Also known as	Investigational product
Sponsor	Ocumension Therapeutics (Shanghai) Co., Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of OT202 in Treating Moderate to Severe Dry Eye (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OT202 conc 0.1% CI brief — competitive landscape report
OT202 conc 0.1% updates RSS · CI watch RSS
Ocumension Therapeutics (Shanghai) Co., Ltd portfolio CI

Frequently asked questions about OT202 conc 0.1%

What is OT202 conc 0.1%?

OT202 conc 0.1% is a Small molecule drug developed by Ocumension Therapeutics (Shanghai) Co., Ltd.

Who makes OT202 conc 0.1%?

OT202 conc 0.1% is developed by Ocumension Therapeutics (Shanghai) Co., Ltd (see full Ocumension Therapeutics (Shanghai) Co., Ltd pipeline at /company/ocumension-therapeutics-shanghai-co-ltd).

Is OT202 conc 0.1% also known as anything else?

OT202 conc 0.1% is also known as Investigational product.

What development phase is OT202 conc 0.1% in?

OT202 conc 0.1% is in Phase 2.

Manufacturer: Ocumension Therapeutics (Shanghai) Co., Ltd — full pipeline
Also known as: Investigational product

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing